---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-184867"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:04:18.413046+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular licenses R100 vector to Astellas for up to $300M per target in ophthalmic gene therapies

## Summary
- $20M upfront from Astellas; eligible for up to $42.5M in option/target substitution fees and $300M per target in milestones.
- Astellas gains exclusive worldwide license to 4DMT's R100 vector for up to three ophthalmic rare monogenic disease targets.
- Tiered royalties from mid-single digits to double-digit sub-teen percentage on net sales; subject to reductions.
- Astellas must use commercially reasonable efforts to develop and commercialize in US and at least two major EU markets.
- 4DMT agreed not to commercialize competing products for 7 years (through July 2030).

## SEC filing metadata
- accession: 0001193125-23-184867
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312523184867/0001193125-23-184867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312523184867/d466246d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-184867
- JSON: https://secwatch.observer/filing/0001193125-23-184867.json
- Plain text: https://secwatch.observer/filing/0001193125-23-184867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.